Standard Biotools (LAB) Net Income towards Common Stockholders (2010 - 2026)

Standard Biotools (LAB) has 17 years of Net Income towards Common Stockholders data on file, last reported at $141.7 million in Q1 2026.

• Net Income towards Common Stockholders for Q1 2026 came in at $141.7 million, up 5420.84% year-over-year; the trailing twelve-month figure through Mar 2026 was $90.2 million (up 216.8% YoY), and the FY2025 annual result was -$74.9 million, up 45.31% from the prior year.
• Net Income towards Common Stockholders improved to $141.7 million in Q1 2026 per LAB's latest filing, from -$2.2 million in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at $141.7 million in Q1 2026 and troughed at -$76.3 million in Q1 2022.
• A 5-year average of -$13.2 million and a median of -$21.0 million in 2023 frame the typical range for Net Income towards Common Stockholders.
• The sharpest annual moves came in 2022 and 2026: Net Income towards Common Stockholders tumbled 305.82% in 2022, then soared 5420.84% in 2026.
• A 5-year view of Net Income towards Common Stockholders shows it stood at -$2.0 million in 2022, then soared by 1156.13% to $20.7 million in 2023, then sank by 231.4% to -$27.2 million in 2024, then surged by 92.02% to -$2.2 million in 2025, then jumped by 6632.69% to $141.7 million in 2026.
• Business Quant data shows LAB's Net Income towards Common Stockholders at $141.7 million in Q1 2026, -$2.2 million in Q4 2025, and -$31.7 million in Q3 2025.